Moderna, Inc. $MRNA Shares Newly Bought by Americana Partners LLC

Key Points

• Americana Partners LLC purchased 7,696 Moderna shares worth approximately $1.48 million during the third quarter. Institutional investors and hedge funds collectively own 75.33% of the company.
• Analyst sentiment remains mixed, with six Buy, fifteen Hold and four Sell ratings; Moderna has an overall “Hold” consensus and an average price target of $107.10.
• Moderna’s personalized cancer-vaccine program is a key long-term catalyst, but declining expected earnings, valuation concerns and recent insider sales—including $33.9 million sold over 90 days—remain significant risks.

Americana Partners LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,696 shares of the company's stock, valued at approximately $1,482,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Western Pacific Wealth Management LP purchased a new position in Moderna during the 3rd quarter worth $29,000. Ramsey Quantitative Systems bought a new stake in Moderna in the 3rd quarter worth about $40,000. Fortitude Family Office LLC boosted its stake in shares of Moderna by 53.1% in the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company's stock worth $43,000 after buying an additional 77 shares during the last quarter. MADDEN SECURITIES Corp bought a new stake in shares of Moderna during the 3rd quarter worth $55,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Moderna during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research analyst reports. Barclays raised their price objective on shares of Moderna from $48.00 to $125.00 and gave the stock an "equal weight" rating in a report on Monday, August 24th. JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a research note on Friday, August 21st. Argus raised Moderna from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a research report on Friday, August 28th. UBS Group reaffirmed a "neutral" rating on shares of Moderna in a research report on Tuesday, September 22nd. Finally, Brookline Capital Markets reiterated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $107.10.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Moderna Trading Down 0.5%

Shares of Moderna stock opened at $221.72 on Friday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $254.48. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm has a market cap of $88.52 billion, a PE ratio of -27.75 and a beta of 1.09. The company has a 50 day simple moving average of $182.49 and a two-hundred day simple moving average of $86.52.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted ($2.13) earnings per share. Analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Insider Activity

In other news, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.